1. |
Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. Sci Transl Med, 2012, 4(165): 165rv13.
|
2. |
Maini R, Henderson KL, Sheridan EA, et al. Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg Infect Dis, 2013, 19(3): 386-392.
|
3. |
Wickramasekaran RN, Jewell MP, Sorvillo F, et al. The changing trends and profile of pneumocystosis mortality in the United States, 1999-2014. Mycoses, 2017, 60(9): 607-615.
|
4. |
Delbove A, Alami H, Tissot A, et al. Pneumocystis pneumonia after lung transplantation: a retrospective multicenter study. Resp Med, 2020, 169: 106019.
|
5. |
Wojarski J, Ochman M, Latos M, et al. Immunosuppressive treatment and its effect on the occurrence of Pneumocystis jiroveci, Mycoplasma pneumoniae, Chlamydophila pnemoniae, and Legionella pneumophila infections/colonizations among lung transplant recipients. Transplant Proc, 2018, 50(7): 2053-2058.
|
6. |
Wang EH, Partovi N, Levy RD, et al. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past. Transpl Infect Dis, 2012, 14(5): 519-525.
|
7. |
Izadi M, Jonaidi Jafari N, Sadraei J, et al. The prevalence of Pneumocystis jiroveci in bronchoalveolar lavage specimens of lung transplant recipients examined by the nested PCR. Jundishapur J Microbiol, 2014, 7(12): e13518.
|
8. |
Zeglen S, Wojarski J, Wozniak-Grygiel E, et al. Procalcitonin Serum Concentration During Pneumocystis Jiroveci Colonization or Pseudomonas Aeruginosa Infection/Colonization in Lung Transplant Recipients. Transplant Proc, 2009, 41(8): 3225-3227.
|
9. |
Lehto JT, Koskinen PK, Anttila VT, et al. Bronchoscopy in the diagnosis and surveillance of respiratory infections in lung and heart-lung transplant recipients. Transpl Int, 2005, 18(5): 562-571.
|
10. |
杨靖波, 刘懿禾, 于立新, 等. 实体器官移植术后重症肺孢子虫肺炎诊治. 实用器官移植电子杂志, 2020, 8(4): 278-281.
|
11. |
Masur H, Brooks JT, Benson CA, et al. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis, 2014, 58(9): 1308-1311.
|
12. |
Smith DE, McLuckie A, Wyatt J, et al. Severe exercise hypoxaemia with normal or near normal X-rays: a feature of Pneumocystis carinii infection. Lancet, 1988, 2(8619): 1049-1051.
|
13. |
Mu XD, Jia P, Gao L, et al. Relationship between radiological stages and prognoses of pneumocystis pneumonia in non-aids immunocompromised patients. Chin Med J (Engl), 2016, 129(17): 2020-2025.
|
14. |
Vogel MN, Brodoefel B, Hierl T, et al. Differences and similarities of cytomegalovirus and pneumocystis pneumonia in HIV-negative immunocompromised patients thin section CT morphology in the early phase of the disease. Br J Radiol, 2007, 80(955): 516-523.
|
15. |
Corpo OD, Laporte GB, Sheppard DC, et al. Diagnostic accuracy of serum (1-3)-β-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect, 2020, 26(9): 1137-1143.
|
16. |
Li WJ, Guo YL, Liu TJ, et al. Diagnosis of pneumocystis pneumonia using serum (1-3)-β-D-Glucan: a bivariate meta-analysis and systematic review. J Thorac Dis, 2015, 7(12): 2214-2225.
|
17. |
Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1, 3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbol, 2012, 50(1): 7-15.
|
18. |
Karageorgopoulos DE, Qu JM, Korbila IP, et al. Accuracy of β-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect, 2013, 19(1): 39-49.
|
19. |
Damiani C, Gal SL, Costa CD, et al. Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1-> 3)-β-D-glucan for differential diagnosis of pneumocystis pneumonia and Pneumocystis colonization. J Clin Microbiol, 2013, 51(10): 3380-3388.
|
20. |
Rose SR, Vallabhajosyula S, Velez MG, et al. The utility of bronchoalveolar lavage beta-D-glucan testing for the diagnosis of invasive fungal infections. J Infect, 2014, 69(3): 278-283.
|
21. |
Salerno D, Mushatt D, Myers L, et al. Serum and bal beta-D-glucan for the diagnosis of Pneumocystis pneumonia in HIV positive patients. Respir Med, 2014, 108(11): 1688-1695.
|
22. |
Salzer HJF, Schäfer G, Hoenigl M, et al. Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia. Respiration, 2018, 96(1): 52-65.
|
23. |
Vogel M, Weissgerber P, Goeppert B, et al. Accuracy of serum LDH elevation for the diagnosis of Pneumocystis jiroveci pneumonia. Swiss Med Wkly, 2011, 141: w13184.
|
24. |
Nyamande K, Lalloo UG. Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis, 2006, 10(5): 510-515.
|
25. |
Ma L, Cissé OH, Kovacs JA. A molecular window into the biology and epidemiology of Pneumocystis spp. Clin Microbiol Rev, 2018, 31(3): e00009-18.
|
26. |
Desoubeaux G, Franck-Martel C, Caille A, et al. Use of calcofluor-blue brightener for the diagnosis of Pneumocystis jirovecii pneumonia in bronchial-alveolar lavage fluids: a single-center prospective study. Med Mycol, 2017, 55(3): 295-301.
|
27. |
Roblot F, Moal GL, Kauffmann-Lacroix C, et al. Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study with focus on immunosuppressive drugs and markers of immune impairment. Scand J Infect Dis, 2014, 46(3): 210-214.
|
28. |
Cruciani M, Marcati P, Malena M, et al. Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J, 2002, 20(4): 982-989.
|
29. |
Summah H, Zhu YG, Falagas ME, et al. Use of real-time polymerase chain reaction for the diagnosis of Pneumocystis pneumonia in immunocompromised patients: a meta-analysis. Chin Med J (Engl), 2013, 126(10): 1965-1973.
|
30. |
Fan LC, Lu HW, Cheng KB, et al. Evaluation of PCR in bronchoalveolar lavage fluid for diagnosis of Pneumocystis jirovecii pneumonia: a bivariate meta-analysis and systematic review. PLoS One, 2013, 8(9): e73099.
|
31. |
Lu Y, Ling G, Qiang C, et al. PCR diagnosis of Pneumocystis pneumonia: a bivariate meta-analysis. J Clin Microbiol, 2011, 49(12): 4361-4363.
|
32. |
Sasso M, Chastang-Dumas E, Bastide S, et al. Performances of four real-time PCR assays for diagnosis of Pneumocystis jirovecii pneumonia. J Clin Microbiol, 2016, 54(3): 625-630.
|
33. |
Gazaignes S, Bergeron A, Menotti J, et al. [Pneumocystis jirovecii and quantitative PCR: pneumonia or colonization?]. Rev Mal Respir, 2020, 37(4): 299-307.
|
34. |
Barbier F, Mer M, Szychowiak P, et al. Management of HIV-infected patients in the intensive care unit. Intensive Care Med, 2020, 46(2): 329-342.
|
35. |
Tu GW, Ju MJ, Xu M, et al. Combination of caspofungin and low‐dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients. Nephrology (Carlton), 2013, 18(11): 736-742.
|
36. |
Simner PJ, Miller S, Carroll KC. Understanding the promises and hurdles of metagenomic next-generation sequencing as a diagnostic tool for infectious diseases. Clin Infect Dis, 2018, 66(5): 778-788.
|
37. |
Gu W, Miller S, Chiu CY. Clinical metagenomic next-generation sequencing for pathogen detection. Annu Rev Pathol, 2019, 14: 319-338.
|
38. |
Chiu CY, Miller SA. Clinical metagenomics. Nat Rev Genet, 2019, 20(6): 341-355.
|
39. |
Wang J, Han Y, Feng J. Metagenomic next-generation sequencing for mixed pulmonary infection diagnosis. BMC Pulm Med, 2019, 19(1): 252.
|
40. |
Irinyi L, Hu Y, Hoang MTV, et al. Long-read sequencing based clinical metagenomics for the detection and confirmation of Pneumocystis jirovecii directly from clinical specimens: a paradigm shift in mycological diagnostics. Med Mycol, 2020, 58(5): 650-660.
|
41. |
Camargo JF, Ahmed AA, Lindner MS, et al. Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts. F1000Res, 2019, 8: 1194.
|
42. |
Li Y, Sun B, Tang X, et al. Application of metagenomic next-generation sequencing for bronchoalveolar lavage diagnostics in critically ill patients. Eur J Clin Microbiol Infect Dis, 2020, 39(2): 369-374.
|
43. |
Fonseca Brito L, Brune W, Stahl FR. Cytomegalovirus (CMV) pneumonitis: cell tropism, inflammation, and immunity. Int J Mol Sci, 2019, 20(16): 3865.
|
44. |
Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant, 2013, 13 Suppl 3: 24-40.
|
45. |
Alvarez B, Arcos J, Fernández-Guerrero ML. Pulmonary infectious diseases in patients with primary immunodeficiency and those treated with biologic immunomodulating agents. Curr Opin Pulm Med, 2011, 17(3): 172-179.
|
46. |
Baddley JW, Winthrop KL, Chen L, et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis, 2014, 73(11): 1942-1948.
|
47. |
Park JW, Curtis JR, Moon J, et al. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis, 2018, 77(5): 644-649.
|
48. |
Green H, Paul M, Vidal L, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc, 2007, 82(9): 1052-1059.
|
49. |
Maschmeyer G, Helweg-Larsen J, Pagano L, et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemoth, 2016, 71(9): 2405-2413.
|
50. |
倪蓓文, 黄洪辉, 王婷, 等. 卡泊芬净联合治疗急性红白血病并发卡氏肺孢子虫肺炎1例. 世界临床药物, 2013, 34(8): 480-482.
|
51. |
Armstrong-James D, Stebbing J, John L, et al. A trial of caspofungin salvage treatment in PCP pneumonia. Thorax, 2011, 66(6): 537-538.
|
52. |
Simonds RJ, Hughes WT, Feinberg J, et al. Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus. Clin Infect Dis, 1995, 21 Suppl 1: S44-S48.
|
53. |
Dao BD, Barreto JN, Wolf RC, et al. Serum peak sulfamethoxazole concentrations demonstrate difficulty in achieving a target range: a retrospective cohort study. Curr Ther Res Clin Exp, 2014, 76: 104-109.
|
54. |
Ice LL, Barreto JN, Dao BD, et al. Relationship of sulfamethoxazole therapeutic drug monitoring to clinical efficacy and toxicity: a retrospective cohort study. Ther Drug Monit, 2016, 38(3): 319-326.
|
55. |
Chang HM, Tsai HC, Lee SS, et al. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS. J Chin Med Assoc, 2016, 79(6): 314-319.
|